Verastem VSTM
NASDAQ VSTM
$8.02 +0.04 (+0.50%)
As of: Sep 4, 2026 · 2:38 PM EDT

Verastem (VSTM) Net Income towards Common Stockholders (2011 - 2026)

Verastem (VSTM) posted quarterly Net Income towards Common Stockholders of -$44.5 million for Q1 2026, little changed year-over-year from -$44.5 million in Q1 2025, and down 1487.92% quarter-over-quarter from $3.2 million in Q4 2025.

Analysis

Verastem (VSTM) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends

Verastem's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$44.5 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders changed 0.11% year-over-year to -$44.5 million; the TTM figure through Mar 2026 stood at -$139.5 million (down 5.54% YoY), while the FY2025 annual figure was -$165.5 million, down 26.66% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$44.5 million, down from $3.2 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $3.2 million in Q4 2025, with the low at -$54.0 million in Q2 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$22.0 million (2022), against an average of -$27.5 million.
  • Peak annual rise in Net Income towards Common Stockholders reached 110.02% in 2025, while the deepest fall reached 192.7% in 2025.
  • Verastem's Net Income towards Common Stockholders stood at -$16.8 million in 2022, then slumped by 80.88% to -$30.4 million in 2023, then fell by 5.19% to -$32.0 million in 2024, then surged by 110.02% to $3.2 million in 2025, then plunged by 1487.92% to -$44.5 million in 2026.
  • Business Quant data shows VSTM's Net Income towards Common Stockholders at -$44.5 million in Q1 2026, $3.2 million in Q4 2025, and -$44.3 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn - -644.37 Mn
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -13.27 Mn
10 Verastem 802.43 Mn 666.08 Mn 36.32 Mn -34.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -34.67 Mn
Mar 31, 2026 -43.98 Mn
Dec 31, 2025 3.20 Mn
Sep 30, 2025 -39.85 Mn
Jun 30, 2025 -25.93 Mn
Mar 31, 2025 -43.41 Mn
Dec 31, 2024 -31.97 Mn
Sep 30, 2024 -37.35 Mn
Jun 30, 2024 -18.43 Mn
Mar 31, 2024 -27.82 Mn
Dec 31, 2023 -30.39 Mn
Sep 30, 2023 -20.19 Mn
Jun 30, 2023 -20.29 Mn
Mar 31, 2023 -19.14 Mn
Dec 31, 2022 -16.80 Mn
Sep 30, 2022 -18.11 Mn
Jun 30, 2022 -21.96 Mn
Mar 31, 2022 -16.99 Mn
Dec 31, 2021 -16.48 Mn
Sep 30, 2021 -22.79 Mn